| Followers | 238 |
| Posts | 15503 |
| Boards Moderated | 1 |
| Alias Born | 03/29/2014 |
Monday, February 24, 2025 8:32:23 PM
I probably didn't explain my point well enough; hence, you missed it.
The Accounts Receivable have to be paid. Money has to be raised to pay the receivables. So they have to sell shares to raise money to pay the bills. As a vendor, Advent is willing to take some of their payment in shares. That is a good thing, because many vendors on this planet are not willing to take shares as payment from a biotech without a revenue stream. And if Advent wasn't taking shares as payment, then they would want cash, so Northwest would have to sell those same shares for cash to those willing and able to buy them from the company. So in the end, it's the same number of shares going out the door.
So the "massive dilution" you reference is the SAME, whether Advent is paid in shares, or someone buys the shares to provide the cash to pay the bills from the company. So there is no benefit to LP to keep the share price down. In fact, her personal share count is also being diluted, in order to pay the bills.
Additionally, the fact that Advent is willing to be paid in shares indicates... to me anyway... that they, Advent, are confident those shares will be worth more in the future.
The Accounts Receivable have to be paid. Money has to be raised to pay the receivables. So they have to sell shares to raise money to pay the bills. As a vendor, Advent is willing to take some of their payment in shares. That is a good thing, because many vendors on this planet are not willing to take shares as payment from a biotech without a revenue stream. And if Advent wasn't taking shares as payment, then they would want cash, so Northwest would have to sell those same shares for cash to those willing and able to buy them from the company. So in the end, it's the same number of shares going out the door.
So the "massive dilution" you reference is the SAME, whether Advent is paid in shares, or someone buys the shares to provide the cash to pay the bills from the company. So there is no benefit to LP to keep the share price down. In fact, her personal share count is also being diluted, in order to pay the bills.
Additionally, the fact that Advent is willing to be paid in shares indicates... to me anyway... that they, Advent, are confident those shares will be worth more in the future.
Recent NWBO News
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
